Clinical trials: Retinoblastoma, open to volunteers
Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma
- Trial name
- NCT06498648
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Retinoblastoma
Retinoblastoma Consolidation in Egyptians
This analysis will evaluate the investigators' institution's specific experience using Ru-106 isotopes, cryotherapy, or transpupillary thermotherapy (TTT) to treat persistent or recurrent RB in patients who previously underwent…
- Trial name
- NCT07530458
- Testing
- transpupillary thermotherapy, Cryotherapy, Brachytherapy
- Volunteers
- 150 people
- Sponsor
- Assiut University
Retinoblastoma, Extraocular
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
Retinoblastoma is the most common intraocular malignancy in infancy and childhood. The overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase.
- Trial name
- NCT04903678
- Testing
- Melphalan
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Retinoblastoma
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95 to 97% of 5-years survival rate.
- Trial name
- PREDIR (NCT03267459)
- Testing
- Dynamic contrast-enhanced MRI
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Phase 1b, Open Label
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
- Conditions
- Phase 1b, Open Label, REC-617, RB1-Negative
- Trial name
- NCT07633756
- Testing
- REC617
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Retinoblastoma, Retinoblastoma, Recurrent
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Retinoblastoma is the most common intraocular malignancy in infancy and childhood,with an estimated 8000 new cases globally each year.The major cause of failure in the management of retinoblastoma remains the persistence or…
- Trial name
- NCT06972602
- Testing
- Topotecan, Collection of aqueous humor, Electroretinogram
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Eye & ENT Hospital of Fudan University